Non-Human Primate (NHP) Applications in Early Discovery & PoC

Are you currently facing long drug development cycles and the challenge of translating preclinical findings to successful clinical outcomes? Creative Biolabs helps you accelerate drug discovery by leveraging our robust non-human primate (NHP) platforms. Our advanced capabilities in preclinical research and toxicology provide high-quality data that directly supports your path to Investigational New Drug (IND) submission, streamlining your development pipeline from early discovery to clinical proof of concept.

Early Discovery & PoC with NHP Models

NHP models provide essential translational data for early-stage therapeutic development, bridging the gap between bench and bedside. Their biological and physiological similarities to humans are critical for assessing a new candidate's safety and efficacy before first-in-human trials.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

Early discovery and proof-of-concept (PoC) studies are critical stages in the drug development pipeline, where therapeutic candidates are evaluated for their potential efficacy, safety, and pharmacology. This phase often involves complex biological questions that cannot be answered by traditional in vitro or rodent models. NHPs are uniquely suited for these studies due to their close phylogenetic relationship with humans, providing a more predictive and clinically relevant system for de-risking novel drug candidates.

• Proof-of-Concept Efficacy Studies: These studies evaluate whether a candidate therapeutic can produce the desired biological effect in a relevant disease model. For complex conditions like neurological, autoimmune, and infectious diseases, NHPs provide an essential model to demonstrate target engagement and therapeutic effect in a system that closely mimics human physiology and pathology. This helps validate the therapeutic hypothesis and provides crucial data for go/no-go decisions.
• Vector/Construct Design & Screening: In the rapidly advancing field of gene therapy, the design and selection of optimal viral vectors, such as adeno-associated viruses (AAVs), is a major challenge. NHPs are a critical tool for evaluating vector biodistribution, tropism, and shedding. This allows researchers to identify the most effective and safest vector/construct designs before moving into costly clinical trials.

Why Choose Us?

Creative Biolabs leverages NHP models because they offer distinct advantages that are often required for regulatory submissions and are difficult or impossible to replicate in other systems.

• Genetic and Immunological Similarities: NHPs share up to 98% of their genetic makeup with humans, which is a major factor for predicting drug metabolism, immune responses, and off-target effects. This is particularly crucial for biologics, vaccines, and advanced therapies, where a human-like immune system is necessary to evaluate immunogenicity.
• Clinical Translational Relevance: NHP models allow for the use of clinical-scale procedures and diagnostic tools, such as advanced imaging and biomarker analysis, making the data highly translatable to human studies. This close parallel reduces the risk of preclinical-to-clinical failure and provides a more reliable foundation for IND submissions.
• Data Types Required for Regulatory Submissions: Regulatory bodies often require data from a non-rodent species to support the safety of a drug candidate. For many large molecules and gene therapies, NHPs are the only pharmacologically relevant species that can provide the necessary safety and toxicology data.

Distributed under Unsplash License, from Unsplash.

Key Applications

NHPs are essential for answering specific questions in key therapeutic areas:

• Gene & Cell Therapy: Assessing vector biodistribution and shedding patterns in different organs. Evaluating long-term transgene expression and durability. Modeling cytokine release syndrome (CRS) for cell-based therapies.
• Infectious Diseases & Vaccines: Developing and evaluating vaccine efficacy against emerging pathogens. Studying disease pathogenesis and evaluating novel antiviral or antimicrobial therapies.
• Neuroscience & CNS Disorders: Providing complex models for studying diseases like Parkinson's and Alzheimer's, which are difficult to replicate in rodents. Assessing the efficacy of CNS-targeting therapeutics and their ability to cross the blood-brain barrier.
• Oncology & Immunology: Evaluating immune-oncology therapies (e.g., CAR-T, bispecifics, checkpoint inhibitors) and their impact on the tumor microenvironment. Assessing immunotoxicity and on-target, off-tumor effects.

How Do Creative Biolabs Support Your Projects?

At Creative Biolabs, our comprehensive service portfolio is designed to provide the specific data you need at every stage of early discovery and PoC. Each of our service entries corresponds to a critical application area, allowing you to build a custom solution for your project.

Translational Impact

Data from our NHP studies is instrumental in de-risking your therapeutic development. By providing a more reliable early proof of concept, we help you make data-driven decisions that can significantly reduce the risk of costly IND failure. Our studies can lead to the early detection of immune responses or toxicity, allowing for proactive mitigation strategies. For instance, NHP biodistribution data is frequently required for gene therapy IND submissions, directly informing your regulatory strategy. This high-fidelity data enhances the predictability of clinical outcomes and supports a smoother transition from preclinical research to human trials.

Frequently Asked Questions

Contact Us

Creative Biolabs stands as your reliable collaborator for employing NHP models in early discovery and proof-of-concept stages. Our extensive expertise and cohesive service platform deliver high-quality translational data essential for expediting your journey to clinical application. Interested in utilizing our NHP platform for your upcoming research? Reach out to our team for further information and project discussions.